Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1 3

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Hematologic Neoplasms 2Recurrence 1Hematologic Tumors 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × Homoharringtonine × Clear all
NCT04926285 2026-03-16

VEN-OM

University of Illinois at Chicago

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms

NCT01844869 2015-01-30

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
6 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00675350 2014-05-12

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
12 enrolled

Hematologic Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡